1. Home
  2. PRAX vs ZION Comparison

PRAX vs ZION Comparison

Compare PRAX & ZION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$345.30

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Logo Zions Bancorporation N.A.

ZION

Zions Bancorporation N.A.

HOLD

Current Price

$68.11

Market Cap

9.4B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
ZION
Founded
2015
1873
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
9.6B
9.4B
IPO Year
2020
2012

Fundamental Metrics

Financial Performance
Metric
PRAX
ZION
Price
$345.30
$68.11
Analyst Decision
Strong Buy
Hold
Analyst Count
15
18
Target Price
$572.13
$65.33
AVG Volume (30 Days)
311.4K
1.2M
Earning Date
05-08-2026
04-20-2026
Dividend Yield
N/A
2.88%
EPS Growth
N/A
21.41
EPS
N/A
4.61
Revenue
N/A
$662,000,000.00
Revenue This Year
N/A
$8.57
Revenue Next Year
$7,758.26
$4.67
P/E Ratio
N/A
$14.83
Revenue Growth
N/A
3.60
52 Week Low
$37.25
$46.21
52 Week High
$392.70
$73.34

Technical Indicators

Market Signals
Indicator
PRAX
ZION
Relative Strength Index (RSI) 47.08 45.57
Support Level $285.26 $67.89
Resistance Level $356.02 $72.87
Average True Range (ATR) 17.13 1.21
MACD -4.00 0.02
Stochastic Oscillator 21.92 52.77

Price Performance

Historical Comparison
PRAX
ZION

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About ZION Zions Bancorporation N.A.

Zions Bancorp is a US regional bank with around $90 billion in total assets as of Sept. 30, 2025. Headquartered in Salt Lake City, Utah, Zions' branch network is in the Western and Southwestern United States and includes seven affiliate banks in these markets. The bank has a heavy focus on small and midsize commercial banking.

Share on Social Networks: